ZIMMER BIOMET HOLDINGS, INC.(ZBH)— Stock Profile, AI Score & Financials
Healthcare · NYSE · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated .
ZIMMER BIOMET HOLDINGS, INC. (ZBH) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ZBH at 65.7/100 on a 32-signal composite quality model, placing it at rank #465 of 2,960 stocks — the top 25% of the AI-ranked universe. ZBH scores in the top quartile across earnings quality (85.3), revenue scale (84.6), institutional flow (82.0). Based on the latest XBRL financial filings (Q2 2026), ZIMMER BIOMET HOLDINGS, INC. reports quarterly revenue of $2.2B, net income of $198.3M, an operating margin of 15.0%. Top institutional holders of ZBH by reported 13-F value include DODGE & COX, BlackRock, HARRIS ASSOCIATES L P, based on the most recent SEC filings. ZBH trades on the NYSE exchange and files with the SEC under CIK 1136869. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ZBH daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for ZIMMER BIOMET HOLDINGS, INC. directly from SEC EDGAR.
AI Quality Score
65.7/100
AI Rank
#465
Revenue
$2.2B
Net Income
$198.3M
Free Cash Flow
$393.6M
Operating Margin
15.0%
ZBH key financials by period
ZIMMER BIOMET HOLDINGS, INC. reported revenue, net income and margins by fiscal period, from SEC filings.
Period
Form
Revenue
Net income
Operating margin
FY 2025
10-K
$8.2B
$705.1M
13.3%
FY 2024
10-K
$7.7B
$903.8M
16.7%
FY 2023
10-K
$7.4B
$1.0B
17.3%
FY 2022
10-K
$6.9B
$231.4M
10.0%
FY 2021
10-K
$6.8B
$401.6M
12.6%
FY 2020
10-K
$6.1B
$-138.9M
1.4%
Institutions holding ZBH
Institutional investors reporting a position in ZIMMER BIOMET HOLDINGS, INC. on SEC Form 13F.
AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Net sales grew 4.8% YoY to $2,177.0M with operating margin expanding to 15.0% from 14.4%, as Paragon 28 and strong ROSA Robot/bone cement sales drove diluted EPS up 34% to $1.03.
Biggest Revenue Drivers
Knees$828.9M+0.4% YoY
Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions
S.E.T.$586.0M+6.4% YoY
Primarily the result of the Paragon 28 acquisition and growth in upper extremities and craniomaxillofacial/thoracic products
Biggest Revenue Drivers
Total revenue: $2,177.0M+4.8% YoY
Knees$828.9M+0.4% YoY
Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions
S.E.T.$586.0M+6.4% YoY
Primarily the result of the Paragon 28 acquisition and growth in upper extremities and craniomaxillofacial/thoracic products
Hips$562.7M+5.0% YoY
Benefited from opportunistic end-of-quarter customer purchases, market growth and new product introductions
Technology & Data, Bone Cement and Surgical$199.4M+21.1% YoY
Primarily due to strong net sales of ROSA Robot and bone cement products
Largest Expense Items
Selling, general and administrative$899.3M+10.4% YoY
Higher variable/bonus selling expenses from increased net sales, Paragon 28-related expenses, higher litigation-related expense, higher bad debt charges and sales force investments
Cost of products sold (excl. intangible amortization)$635.5M+7.3% YoY
Higher sales volume, higher manufacturing costs, Paragon 28 inventory step-up to fair value, and net sales price declines, partly offset by favorable product mix
Intangible asset amortization$163.4M+1.7% YoY
Increased due to the Paragon 28 acquisition
Research and development$104.8M-7.5% YoY
Completion of initial EU Medical Device Regulation compliance spending, lower project spending and restructuring savings, partly offset by Paragon 28 and Monogram R&D
Margins: Operating profit margin rose to 15.0% of net sales from 14.4%, as lower R&D and acquisition/integration costs offset higher cost of products sold (29.2% vs 28.5%, from manufacturing costs and Paragon 28 inventory step-up) and higher SG&A (41.3% vs 39.2%).
Watch Items from the Filing
Displaced China distributors have formally and informally raised legal claims amid an ongoing overhaul of the go-to-market model there; the company cannot reasonably estimate losses beyond current accruals.
The Global Foot & Ankle reporting unit's estimated fair value exceeded its carrying value by only ~5%, a thin cushion since its assets stem almost entirely from the Paragon 28 acquisition.
Following a Supreme Court ruling invalidating IEEPA tariffs, the company expects to recover the full ~$77M it previously paid and already booked a ~$30M favorable cost-of-sales adjustment in H1 2026.
$1,201.5M of debt is now classified as current, including $571.5M of notes due December 2026 and $600.0M due February 2027.
Subsequent to quarter-end, the company signed agreements for new pain management and surgical technology with ~$245M initial cash consideration plus up to $210M in contingent milestone payments.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
